Table 2.

Engraftment in Recipients of Ex Vivo Expanded Cells and MDACC and CIBMTR Controls.

Engraftment	Recipients of Ex Vivo Expanded Cells (N = 24)	MDACC Controls (N = 60)	P Value*	CIBMTR Controls (N = 80)	P Value†
Neutrophil engraftment
No. of patients	23	51		67
Time to engraftment — days
Median	15	21	0.08	24	<0.001
Range	9–42	6–45		12–52
Cumulative incidence — % (95% CI)
By 26 days	88 (66–96)	62 (48–73)	0.006	53 (41–63)	<0.001
By 42 days	96 (74–99)	83 (71–91)	0.05	78 (67–86)	0.005
Platelet engraftment
No. of patients	18	38		37
Time to engraftment — days
Median	42	41	0.33	49	0.03
Range	15–62	26–126		18–264
Cumulative incidence — % (95% CI)
By 60 days	71 (48–85)	52 (38–63)	0.10	31 (21–41)	<0.001
By 180 days	75 (53–88)	63 (50–74)	0.28	46 (35–58)	0.01

^*P values are for the comparison between recipients of STRO-3+ mesenchymal precursor cells and MDACC controls.

^†P values are for the comparison between recipients of STRO-3+ mesenchymal precursor cells and CIBMTR controls.